| __timestamp | Agios Pharmaceuticals, Inc. | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 334800000 |
| Thursday, January 1, 2015 | 35992000 | 337300000 |
| Friday, January 1, 2016 | 50714000 | 358100000 |
| Sunday, January 1, 2017 | 71124000 | 402600000 |
| Monday, January 1, 2018 | 114145000 | 462600000 |
| Tuesday, January 1, 2019 | 132034000 | 512000000 |
| Wednesday, January 1, 2020 | 149070000 | 577900000 |
| Friday, January 1, 2021 | 121445000 | 687000000 |
| Saturday, January 1, 2022 | 121673000 | 844000000 |
| Sunday, January 1, 2023 | 119903000 | 831000000 |
| Monday, January 1, 2024 | 156784000 | 935000000 |
Unlocking the unknown
In the dynamic world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Catalent, Inc. and Agios Pharmaceuticals, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Catalent's SG&A expenses surged by approximately 148%, reflecting its aggressive expansion and operational scaling. In contrast, Agios Pharmaceuticals saw a more modest increase of around 526% over the same period, indicating a steady growth trajectory.
Catalent's expenses peaked in 2024, reaching nearly $935 million, while Agios's data for 2024 remains elusive, highlighting potential reporting gaps. This comparison underscores the diverse strategies companies employ in cost management, with Catalent focusing on rapid growth and Agios on sustainable development. As the pharmaceutical landscape evolves, these insights provide valuable lessons in balancing growth with financial prudence.
Comparing SG&A Expenses: AbbVie Inc. vs Catalent, Inc. Trends and Insights
Comparing SG&A Expenses: Pfizer Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
Sanofi or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Genmab A/S vs Catalent, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: Catalent, Inc. vs Veracyte, Inc.
Perrigo Company plc and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for MorphoSys AG and Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Agios Pharmaceuticals, Inc. or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Agios Pharmaceuticals, Inc. and MiMedx Group, Inc.